EPO and tauopathy: Chronic dosing of cTfRMAb-EPO both reduced locomotion hyperactivity and altered anxiety-like behavior in the PS19 mice, which suggests that administering the BBB-penetrating EPO analog had a positive effect in this mouse model of tauopathy (Figure 1).